News

To enable deeper stakeholder understanding of Astellas' efforts to continue to create value for sustainable growth, we have published the annual report as an integrated report. In order to provide timely information, from FY2019, we have started publishing the Annual Report here on this website . The information in the online version "Annual Report" will be updated to the latest information as...

TOKYO, October 15, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that subsidiaries of Astellas will transfer their marketing authorizations, trademark, and related contracts for “Nasea (5HT 3 receptor antagonist-type antiemetic)”, “Perdipine (calcium channel blocker)”, and “Oldeca (sustained release calcium antagonist)” (the...

TOKYO, October 1 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced it will invest nearly $13 million into two innovation incubators operated by LabCentral, a premier United States-based laboratory facility for next-generation biotech startups. This initiative, combined with the more than $1 billion Astellas has previously committed to...

- Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response - - Findings Presented Today at an Oral Session at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona - TOKYO and BOTHELL, Wash., September 28, 2019 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503,...